148 results about "Coating drugs" patented technology

The invention relates to a pharmaceutical composition comprising benzgalantamine and uses and methods for the preparation thereof. The present invention provides a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. The pharmaceutical composition could be used in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further provides a method for preparing the pharmaceutical composition.

The invention belongs to the technical field of biological medicines and micro-nano motors, and particularly relates to a self-driven micro-motor system for treating helicobacter pylori gastritis and a preparation method of the self-driven micro-motor system. A self-driven micro-motor system with an active targeting function is constructed, the drug coated on the PLGA layer can be any substance with antibacterial activity or capable of promoting gastric mucosa repair, and the drug loading capacity and the sustained release time can be adjusted by adjusting the thickness of the PLGA interlayer. The selection of the enteric coating layer mainly considers the good electrostatic targeting property and pH response release property of the enteric coating layer, and various types of enteric coatings can be selected to adjust pH nodes released by the shell.

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The invention relates to a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. Further the invention relates to the pharmaceutical composition for use in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further relates to a method for preparing the pharmaceutical composition.

The invention belongs to the field of functional composite microbial preparations, and particularly discloses a microbial agent and GABA compounded composition and application thereof in promoting growth and development of children. The composition is prepared from a freeze-dried bacterial agent and a GABA (gamma-aminobutyric acid) compound, wherein the freeze-dried bacterial agent comprises lactobacillus johnsonii YH1136 and lactobacillus helveticus Helveticus; the GABA compound is prepared by loading GABA with the purity of greater than or equal to 98% on a nano cellulose carrier, and the loading rate is 20-35%. The composition realizes high survival rate of the microbial inoculum and targeted slow release of GABA through a freeze-drying process and enteric coating. Experiments show that the composition can significantly improve the serum GH / IGF-1 level, the bone mineral density and the body growth rate, and has a synergistic effect when combined with the vitamin D3. According to the invention, the problems of single strain function, low GABA utilization rate and gastric acid damage in the prior art are solved, and an efficient and safe solution is provided for children growth and development intervention.

A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

The invention relates to the technical field of traditional Chinese medicine extract preparation, and discloses taste-masking enteric-coated traditional Chinese medicine extract particles which comprise drug-loaded pellets and enteric-coated coatings coating the drug-loaded pellets. The invention relates to a drug-loaded pellet. The coating comprises 20-45 parts of pure powder of the traditional Chinese medicine extract and 5-10 parts of dextrin; according to the taste-masking enteric-coated traditional Chinese medicine extract particle and the preparation method thereof, a stable barrier is formed in gastric juice through a carboxymethyl chitosan-lipidosome copolymer coating, and the degradation rate of effective components is reduced to 1t from 40-60% of a traditional preparation; the pH-responsive coating ensures that the rapid release rate of the intestinal tract is as high as 90%, the bioavailability is improved by 2-3 times, the bitter taste is completely covered by the coating layer, and the coating layer can be mixed with food to feed pets; the prepared sustained-release dosage form prolongs the action time of the medicine, reduces the medication frequency, reduces the medication cost of pet owners, and improves pet welfare.

A dosage form has a core with at least one biologically active ingredient, an intermediate coating layer (ICL), and an enteric coating layer (ECL). The ICL has at least one polymer, at least one alkaline agent, and at least one release acceleration agent. The ECL has at least one polymer. A method for obtaining the dosage form coats the ICL on the core via spray coating, followed by the coating of the ECL on the ICL via spray coating. The dosage form provides accelerated drug release at values of pH 3 to pH 6, with at least 80% drug release within 60 min at pH values 3 and 5.

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The application discloses a high-activity UGT1A1 enzyme based on tree shrew and a feed composition for enhancing alcohol metabolism. The catalytic efficiency of the recombinant tree shrew UGT1A1 enzyme on ethanol is significantly higher than that of human isozyme. The core of the application is to provide a complex feed system containing the enzyme, which solves the key bottleneck of poor stability and low delivery efficiency of exogenous enzymes in application through the synergistic effect of enzyme stabilizers, cell penetration enhancers, enteric coatings and coenzyme supply agents. Animal experiments show that the composition can safely and effectively accelerate in vivo alcohol elimination and reduce blood ethanol concentration, and can be used for developing alcoholism products, acute alcoholism treatment drugs and alcoholic liver disease prevention preparations.

The present invention belongs to the technical field of pharmaceutical formulations, specifically relates to a controlled-release tablet of loxoprofen sodium, its preparation method, and use. The controlled-release tablet comprises a drug-containing immediate-release layer, a drug-containing core layer, and a drug-containing sustained-release layer, the drug-containing core layer comprising a plain tablet core, an enteric coating film, and a sealing coating film. The preparation method includes granulating the raw materials for the drug-containing immediate-release layer and the drug-containing sustained-release layer, respectively, wet granulating the raw materials for the plain tablet core and compressing them into tablets, followed by sequentially applying a first sealing coating, a second enteric coating, and a third sealing coating to obtain a drug-containing core, placing the drug-containing core on the drug-containing sustained-release layer granules and pre-compressing them, and then placing the drug-containing immediate-release layer granules on the pre-compressed tablet, compressing them, and coating them to obtain the drug-containing core. The present invention achieves the sustained-release effect of the loxoprofen sodium tablet core by designing the single-layer structure, raw materials, and coating layer components of the dry-coated tablet, thereby achieving 12-hour in vivo efficacy and improving patient compliance.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating pleural effusion and peritoneal effusion and a preparation method thereof.The traditional Chinese medicine preparation is prepared from, by weight, 10-50 parts of traditional Chinese medicine extract, 30-70 parts of filler, 5-20 parts of enteric coating material, 5-15 parts of HPMC, 0.5-2 parts of triethyl citrate and 0.25-1.5 parts of magnesium stearate; poria cocos, polyporus umbellatus, rhizoma alismatis, astragalus membranaceus, curcuma zedoary, cassia twig, oldenlandia diffusa, sculellaria barbata, semen coicis and traditional Chinese medicine extracts are used as cores, the stability of volatile drugs is improved through an inclusion technology, and the volatile drugs are entrapped in a pH intelligent response type enteric coating material composed of aromatic ring-containing vinyl monomers, ethyl acrylate, DMAEMA and MAA. The traditional Chinese medicine preparation has the synergistic effect of efficiently inducing diuresis, activating blood circulation and eliminating tumors and enteric-coated long-acting directional delivery, and is suitable for patients with pleural effusion and peritoneal effusion, especially malignant effusion.

The invention provides a bromocriptine mesylate enteric-coated tablet and a preparation method thereof. Specifically, the bromocriptine mesylate enteric-coated tablet comprises a tablet core and an enteric coating layer wrapping the tablet core. The enteric-coated tablet disclosed by the invention is simple in process, good in stability and small in gastrointestinal side effect, the bioavailability of the enteric-coated tablet is more than two times that of a common tablet sold in the market, the dosage is expected to be reduced, the side effect is further reduced, and the enteric-coated tablet has excellent clinical value.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

The invention relates to the technical field of biological medicine, and discloses a ROS / pH dual-response carrier-based drug delivery system, which comprises an inner core, a response layer and a targeting layer, wherein the inner core is composed of a poly (beta-amino ester) polymer, and the poly (beta-amino ester) polymer is used for coating a drug; the response layer is composed of an ROS sensitive connecting arm wrapping the outer side of the poly (beta-amino ester) polymer; the targeting layer is composed of heart targeting peptide, and the heart targeting peptide is covalently coupled to the inner side of the ROS sensitive connecting arm; according to the present invention, the cardiac targeting peptide is used for the specific binding with the myocardial cell membrane surface receptor, and the ROS sensitive connecting arm is broken in the high ROS environment, such that the poly (beta-amino ester) polymer is dissolved in the lysosome acid environment so as to pertinently release the drug, and the preparation method and the application thereof are provided. Targeted delivery and targeted release of the drug delivery system are achieved, and the drug delivery system can serve as a drug carrier to be applied to treatment of metabolic cardiovascular diseases.

This utility model relates to the technical field of coating devices, specifically a coating device for the enteric coating layer of bisacodyl enteric-coated tablets. It includes a cabinet with a roller inside. A rotating ring is connected to the left side wall of the cabinet, and the left end of the rotating ring is rotatably connected to the inner left side wall of the cabinet via a bearing. In operation, bisacodyl tablets are placed into the roller, the door is closed, and a motor drives the drive wheel, transmission belt, driven wheel, rotating ring, and roller to rotate. Support rollers provide support and improve the stability of the roller's rotation. A peristaltic pump draws and delivers the coating solution to the nozzle of a spray gun. The spray gun is connected to a compressed air pipeline, and the compressed air is used to evenly spray the coating solution onto the surface of the bisacodyl tablets for coating. The rotation of the roller causes the tablets to continuously rotate, ensuring the uniformity of the coating solution spray, thereby effectively coating the surface of the bisacodyl tablets with an enteric coating layer.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The invention discloses methacrylic acid-acrylate copolymer latex for an enteric coating material and a preparation method of the methacrylic acid-acrylate copolymer latex. The emulsifier-free methacrylic acid-acrylate copolymer latex enteric drug coating material is prepared by using an amphiphilic macromolecular reversible addition chain scission chain transfer reagent (RAFT reagent) in combination with an emulsion polymerization method (RAFT emulsion polymerization method). The innovation point of the invention is that the methacrylic acid-acrylate copolymer latex enteric coating material without the emulsifier can be prepared by the RAFT emulsion polymerization method, the polymer generated in the polymerization process is reduced, the use of the emulsifier harmful to health is avoided, the efficiency of the polymer latex in the process of removing the unreacted monomer in vacuum can be improved, and the preparation process is simple. The protection on the enteric-coated medicine is more effective.

A method for manufacturing a tablet, preferably a 3D printable pharmaceutical product (100). The method as described herein comprises repeated steps of: providing a layer of a homogeneous powder formulation (1), the formulation comprising a first excipient (2) and an active pharmaceutical ingredient (3). The tablet comprising a core and an enteric coating. Preferably the core comprises an active pharmaceutical ingredient (API).

The invention discloses a preparation method of a magnesium glycinate enteric-coated sustained-release capsule, and relates to the technical field of preparation of enteric-coated sustained-release capsules, and the preparation method is technically characterized by comprising the following steps: preparing a magnesium glycinate pellet: mixing magnesium glycinate with microcrystalline cellulose, starch and cane sugar to form uniform powder, adding the mixed powder into a centrifugal granulating and coating machine, and carrying out granulation and coating to obtain the magnesium glycinate pellet; taking hydroxypropyl methyl cellulose or a methyl cellulose solution as an adhesive, and performing centrifugal granulation at four stages of nucleation, coalescence, lamination and rolling compaction to obtain magnesium glycinate pellets; the nucleation is that the initial particles attract and are connected with one another due to the formation of a three-phase structure in the wetting process of the adhesive; the coalescence is that parent nuclei are combined to form larger particles due to random collision among the large particles; through a synergistic process of four-stage centrifugal granulation, specific-ratio slow-release coating and HPMCP enteric coating, efficient and accurate controlled release of magnesium glycinate is realized, and the problem of too fast release caused by insufficient weight gain of the slow-release coating is effectively avoided.

The present invention discloses oral MANF microcapsules and their use in the preparation of a preparation for treating ulcerative colitis. Using sodium alginate, hyaluronic acid, and MANF protein as raw materials, the present invention prepares MANF sodium alginate hyaluronic acid composite hydrogel microspheres using a simple and gentle gas shearing method. These microspheres are then emulsified and coated with Eudragit S 100 as an enteric coating material to prepare the oral MANF microcapsules. Animal experiments have confirmed that oral MANF microcapsules have no toxic side effects and that MANF can be effectively delivered to the inflamed colonic tissue of mice with ulcerative colitis. Oral administration of MANF microcapsules significantly alleviates symptoms in mice with ulcerative colitis, improves intestinal flora composition, and demonstrates significantly superior efficacy compared to intravenous injection of the same MANF dose.

A drug delivery device includes an ingestible pill including an enteric coating that covers a patch which defines therein a chamber, the patch being constructed to allow entry of liquid into the chamber. The patch includes at least one raised pouch that protrudes outwardly from the patch and which is in fluid communication with the chamber. The at least one raised pouch includes at least one drug-delivery needle. A gas-generating substance is disposed in the chamber. The gas-generating substance is configured to release gas after the liquid has entered the chamber, the gas being flowable into the at least one raised pouch.

This application provides a pharmaceutical composition comprising: an active ingredient, a filler, a disintegrant, and optionally one or more of a binder, a flow aid, and a lubricant. It also provides an enteric-coated tablet comprising (1) a core containing the aforementioned pharmaceutical composition; (2) an optional insulating layer; and (3) an enteric coating layer. The active ingredient in the enteric-coated tablet is not released in the stomach but is released in the intestines, preventing the active ingredient in the composition from degrading in the acidic environment of the stomach.

The invention discloses a gliquidone multilayer sustained-release tablet and a preparation method thereof, and belongs to the technical field of medical products, the gliquidone multilayer sustained-release tablet comprises a first tablet core and a second tablet core containing gliquidone, the first tablet core is coated with an isolation layer, and the isolation layer and the outer layer of the second tablet core are coated with an outer coating; the first tablet core comprises metformin, sodium bicarbonate, microcrystalline cellulose and resistant starch; the isolating layer comprises an enteric coating. The first tablet core is coated with the enteric coating, so that the dissolution property is greatly reduced under the acidic condition in the stomach, the stimulation of metformin to the stomach is reduced, and the comfort level of the stomach is improved; the metformin is gradually released in intestines; gliquidone is gradually released in gastrointestinal tracts, and is synergistically hypoglycemic with metformin; the resistant starch and the microcrystalline cellulose have a slow release effect, promote intestinal tract movement and improve the comfort of intestinal tracts; the sodium bicarbonate can absorb lactic acid rise caused by metformin accumulation.

The invention provides a nicotine sustained-release capsule, the nicotine sustained-release capsule comprises a content, the content comprises a sustained-release pellet, the sustained-release pellet comprises an active core, a first coating layer and a second coating layer which are sequentially arranged from inside to outside, the active core comprises at least one of nicotine or a nicotine derivative, the first coating layer comprises a first adhesive, and the second coating layer comprises a second adhesive. The second coating layer comprises a second adhesive, and the second coating layer is an enteric coating; through the design of the nicotine sustained-release capsule dosage form, the drug release rate can be delayed, the stable blood concentration can be maintained, the drug effect duration can be prolonged, the smoking process of'low-dose sustained release 'can be simulated, and the emotion and physiological reaction in the smoking cessation process can be improved; in addition, the design of the double-layer coating is also helpful for stabilizing the fluctuation of the blood concentration, and a safer, more continuous and milder nicotine release process is realized.

The invention provides an aspirin enteric-coated composition and a preparation method thereof, and the aspirin enteric-coated composition comprises enteric-coated particles, auxiliary material particles and additional auxiliary materials, the enteric-coated particle comprises aspirin powder, a sustained-release coating layer and an enteric coating layer, the preparation is a multi-particle system, and raw material medicines are only in contact with auxiliary materials of the isolation coating layer, so that the risk that the raw materials and the auxiliary materials are incompatible is reduced; the release of the raw material particles from the composition is jointly controlled by the sustained-release coating layer and the enteric coating layer, so that a multi-particle system is prepared, the burst release phenomenon generated after taking is avoided, and the drug release is uniform. The preparation is granules, a flavoring agent is added, the preparation is more suitable for children to take, the enteric-coated granules can realize multi-dose administration, and the drug release behavior cannot be changed by dose division; fluidized bed coating is used, conditions in the coating process are mild, multiple layers of coatings are arranged outside raw material particles, solvent residues are reduced, ASP hydrolysis is avoided, and the stability of the preparation in the preparation and storage process is improved.

Disclosed are capsule devices, systems, and methods for individualized controlled release of multiple payloads. In some aspects, a multi-segment capsule device includes a capsule assembly comprising a body and a cap, wherein the cap is dissolvable in a fluid, and wherein the body includes an enteric coating capable of preventing or slowing dissolution of the body in the fluid; a plurality of capsule segments contained in the capsule assembly comprising at least a first capsule segment and a second capsule segment, wherein each of the plurality of capsule segments includes an interior capable of storing an individual payload substance, and wherein the first capsule segment is adjacent to the cap in the capsule assembly; and at least one enteric barrier positioned between and separating two capsule segments in the capsule assembly, wherein the at least one enteric barrier includes one or more enteric polymers within a matrix material.